Status | Study |
Completed |
Study Name: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Condition: Accelerated Phase Chronic Myelogenous Leukemia Acute Leukemias of Ambiguous Lineage Date: 2010-10-29 Interventions: Drug: Akt inhibitor MK2206 Giv |
Active, not recruiting |
Study Name: Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Condition: Renal Cancer Date: 2007-04-10 Interventions: Biological: Dendritic Cell Tumor Fusion Vaccine |
Active, not recruiting |
Study Name: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Condition: Leukemia Myelodysplastic Syndromes Blastic Plasmacytoid Date: 2006-11-08 Interventions: Drug: DT388IL3 Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five day |
Active, not recruiting |
Study Name: Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Condition: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder Acute Undifferentiated Leukemia Date: 2001-04-10 Interventions: Drug: fludarabine phosphate Gi |